Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

Overview

• Lilly’s oral weight-loss pill Foundayo, which logged 3,707 U.S. prescriptions in its second week per Friday’s Reuters report citing IQVIA, trailed Novo Nordisk’s oral Wegovy at a similar point with 18,410.
• Lilly shares fell after Friday’s data showed the slower Foundayo uptake and a small week-over-week dip in broader GLP‑1 prescriptions, according to IQVIA figures discussed by Yahoo Finance.
• Analysts kept bullish views after the Kelonia deal, with Barclays’ Emily Field at $1,350 and Scotiabank’s Louise Chen at $1,300, pointing to Lilly’s obesity leadership and 2026 revenue guidance of $80–$83 billion.
• Lilly agreed to buy Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront and up to $3.75 billion in milestones, with closing targeted for the second half of 2026 to build an oncology pipeline.
• Foundayo offers a once-daily pill option for people who avoid injections, and Lilly is expanding supply with a $3.5 billion Pennsylvania facility to keep high-demand drugs available.